
Augmented expression of superoxide dismutase 2 mitigates progression and rupture of experimental abdominal aortic aneurysm

Huimin Yan^{1,2*}, Ying Hu^{1,2}, Yang Lyu³, Antonina Akk¹, Angela C. Hirbe³, Samuel A. Wickline¹, Hua Pan¹, Elisha D.O. Roberson¹, and Christine T.N. Pham^{1,2*}

Supplemental Figures



HA F-actin DAPI

Figure S1. Uptake of HA-SOD2 mRNA NP *in vitro*. Bone-marrow-derived macrophages were left media or transfected with fluorescein-labeled HA-SOD2 mRNA NP for 4 hours then analyzed by confocal microscopy. NP = green; F-actin = red; DAPI (blue) stains nuclei. Scale bar = $20 \mu m$




Figure S2. In vivo uptake of HA-SOD2 mRNA NP. (A) Elastase-perfused mice were injected i.v. with HBSS or fluorescein-HA-SOD2 mRNA NP on day 9 and IVIS of aortas were obtained 7 and 24 hours after injection. (B) Intensity of NP fluorescence in major organs at 7 and 24 hours after fluorescein-HA-SOD2 mRNA NP injection. (C) Mice were perfused with elastase on day 0, administered fluorescein-HA-SOD2 mRNA NP i.v. on day 9 post-elastase perfusion (mRNA= 1 μ g per treatment) and fluorescence assessed in aortic tissue at 24 hours after injection. Aortic sections were examined for NP (green) and MOMA-2 (red). Colocalization appears yellow (arrow). DAPI (blue) stains nuclei. Scale bars = 50 μ m, insert box = 25 μ m.




Figure S3. Uptake of HA-SOD2 mRNA NP in the circulation. Mice were injected i.v. with HBSS or fluorescein-labeled HA-SOD2 mRNA NP on day 9 post-elastase perfusion and sacrificed 30 min or 1 h after injection. Blood was obtained, RBC lysed, and WBC analyzed by flow cytometry. (A) Cell types were identified by size and granularity. (B) NP can be seen internalized by a small percentage of monocytes at both time points. (C) Quantification of NP internalization in different cell populations.

Treatment Parameters	HBSS control	HA coated Scrambled NPs	HA coated SOD2 mRNA NPs
WBC (10 ³ /µl)	8.718 ± 0.386	9.395± 1.232	7.545 ± 1.569
RBC (10 ⁶ /µl)	8.743 ± 0.453	9.115 ± 0.193	8.375 ± 0.712
HGB (g/dL)	12.18 ± 0.230	11.10 ± 0.286	10.48 ± 0.966
Platelet $(10^3/\mu l)$	451.8 ± 143.7	456.6 ± 173.4	469.8 ± 164.4
HCT (%)	43.58 ± 2.070	41.03 ± 0.927	41.93 ± 0.904
MCV	47.25 ± 1.164	45.00 ± 0.385	44.80 ± 0.593
МСН	13.84 ± 0.316	12.15 ± 0.096	12.63 ± 0.384
МСНС	29.26 ± 1.396	27.05 ± 0.132	27.60 ± 0.584

Table 1 Hematologic parameters in mice treated with nanoparticles

Table 2 Chemical parameters in mice treated with nanoparticles

Treatment Parameters	HBSS control	HA coated Scrambled NPs	HA coated SOD2 mRNA NPs
BUN (mg/dL)	32.06 ± 1.590	30.90 ± 2.465	32.93 ± 1.275
Creat (mg/dL)	0.347 ± 0.037	0.338 ± 0.009	0.339 ± 0.024
ALKP (U/L)	74.70 ± 6.533	73.02 ± 7.407	67.61 ± 3.585
AST (U/L)	48.31 ± 3.820	48.80 ± 7.017	49.17 ± 5.281
ALT (U/L)	38.73 ± 10.59	41.80 ± 9.272	42.99 ± 10.96

Figure S4. Toxicity profiles of NP following repeated (x3) injections




Figure S5. Proteomic profiling in TGF- β blockade model of AAA following HA-SOD2 mRNA NP administration. (A) Heatmaps of significantly enriched pathways. (B) Enhancement of key protein components following HA-SOD2 mRNA NP treatment. *P < 0.001.




Figure S6. Contribution of SOD2 in the maintenance of mitochondrial redox balance. (A) Volcano plot of differential expressed proteins (p<0.05 and fold change >1.1) for each pathway after HA-SOD2 mRNA treatment. (B) GSEA and heatmaps of significantly enriched pathways in mitochondria following SOD2 augmentation in TGF- β blockade model of AAA.